Evidence map›Paper›PMID 34789293›Full record

ArticleVirology journal2021

Re-emergence of Gamma-like-II and emergence of Gamma-S:E661D SARS-CoV-2 lineages in the south of Brazil after the 2021 outbreak.

Mauro M Oliveira, Michelle O Schemberger, Andreia A Suzukawa, Irina N Riediger, Maria do Carmo Debur, Guilherme Becker, Paola Cristina Resende, Tiago Gräf, Eduardo Balsanelli, Valter Antônio de Baura and 15 more

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Mauro M Oliveira *Laboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Michelle O Schemberger *Laboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Andreia A Suzukawa *Laboratório de Biologia Básica de Células Tronco, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Irina N RiedigerLaboratório Central do Estado do Paraná, LACEN, Curitiba, Paraná, Brazil.
Maria do Carmo DeburLaboratório Central do Estado do Paraná, LACEN, Curitiba, Paraná, Brazil.
Guilherme BeckerLaboratório Central do Estado do Paraná, LACEN, Curitiba, Paraná, Brazil.
Paola Cristina ResendeLaboratórios de Vírus Respiratórios e do Sarampo (LVRS), Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil.
Tiago GräfInstituto Gonçalo Moniz, FIOCRUZ, Salvador, Bahia, Brazil.
Eduardo BalsanelliDepartamento de Bioquímica e Biologia Molecular, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil.
Valter Antônio de BauraDepartamento de Bioquímica e Biologia Molecular, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil.
Emanuel M de SouzaDepartamento de Bioquímica e Biologia Molecular, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil.
Fábio O PedrosaDepartamento de Bioquímica e Biologia Molecular, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil.
Lysangela R AlvesLaboratório de Regulação da Expressão Gênica, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Lucas BlanesLaboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Sheila Cristina NardelliLaboratório de Pesquisa em Apicomplexa, Carlos Chagas Institute, FIOCRUZ, Curitiba, Paraná, Brazil.
Alessandra M AguiarLaboratório de Biologia Básica de Células Tronco, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Letusa AlbrechtLaboratório de Pesquisa em Apicomplexa, Carlos Chagas Institute, FIOCRUZ, Curitiba, Paraná, Brazil.
Dalila ZanetteLaboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Andréa R ÁvilaLaboratório de Pesquisa em Apicomplexa, Carlos Chagas Institute, FIOCRUZ, Curitiba, Paraná, Brazil.
Luis Gustavo MorelloLaboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Fabricio K MarchiniLaboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Hellen G Dos SantosInstituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Fabio PassettiLaboratório de Regulação da Expressão Gênica, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Bruno DallagiovannaLaboratório de Biologia Básica de Células Tronco, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil.
Helisson FaoroLaboratório de Ciências e Tecnologias Aplicadas Em Saúde, Instituto Carlos Chagas, FIOCRUZ, Curitiba, Paraná, Brazil. helisson.faoro@fiocruz.br.
Fundação Carlos Chagas · BRFundação Oswaldo Cruz · BRUniversidade Federal do Paraná · BR

Funding

CNPq/Ministério da Ciência, Tecnologia e Inovação/Ministério da Saúde 403276/2020-9Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.504690/2020-00Inova Health System VPPIS-001-FIO-18-52Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 422329/2019-9Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 442338/2019-8Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 442339/2019-4Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 442375/2019-0Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 442376/2019-7Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 442381/2019-0Programa de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas 442421/2019-2
6 · The paper itself

Abstract

backgroundWe report a genomic surveillance of SARS-CoV-2 lineages circulating in Paraná, southern Brazil, from March 2020 to April 2021. Our analysis, based on 333 genomes, revealed that the first variants detected in the state of Paraná in March 2020 were the B.1.1.33 and B.1.1.28 variants. The variants B.1.1.28 and B.1.1.33 were predominant throughout 2020 until the introduction of the variant P.2 in August 2020 and a variant of concern (VOC), Gamma (P.1), in January 2021. The VOC Gamma, a ramification of the B.1.1.28 lineage first detected in Manaus (northern Brazil), has grown rapidly since December 2020 and was thought to be responsible for the deadly second wave of COVID-19 throughout Brazil.

methodsThe 333 genomic sequences of SARS-CoV-2 from March 2020 to April 2021 were generated as part of the genomic surveillance carried out by Fiocruz in Brazil Genomahcov Fiocruz. SARS-CoV-2 sequencing was performed using representative samples from all geographic areas of Paraná. Phylogenetic analyses were performed using the 333 genomes also included other SARS-CoV-2 genomes from the state of Paraná and other states in Brazil that were deposited in the GISAID. In addition, the time-scaled phylogenetic tree was constructed with up to 3 random sequences of the Gamma variant from each state in Brazil in each month of 2021. In this analysis we also added the sequences identified as the B.1.1.28 lineage of the Amazonas state and and the Gamma-like-II (P.1-like-II) lineage identified in different regions of Brazil.

resultsPhylogenetic analyses of the SARS-CoV-2 genomes that were previously classified as the VOC Gamma lineage by WHO/PANGO showed that some genomes from February to April 2021 branched in a monophyletic clade and that these samples grouped together with genomes recently described with the lineage Gamma-like-II. Additionally, a new mutation (E661D) in the spike (S) protein has been identified in nearly 10% of the genomes classified as the VOC Gamma from Paraná in March and April 2021.Finally, we analyzed the correlation between the lineage and the Gamma variant frequency, age group (patients younger or older than 60 years old) and the clinical data of 86 cases from the state of Paraná.

conclusionsOur results provided a reliable picture of the evolution of the SARS-CoV-2 pandemic in the state of Paraná characterized by the dominance of the Gamma strain, as well as a high frequencies of the Gamma-like-II lineage and the S:E661D mutation. Epidemiological and genomic surveillance efforts should be continued to unveil the biological relevance of the novel mutations detected in the VOC Gamma in Paraná.

Indexed as

SARS-CoV-2BrazilCOVID-19Disease OutbreaksHumansMiddle AgedMutationPhylogenyPopulation SurveillanceSpike Glycoprotein, CoronavirusWhole Genome SequencingSpike Glycoprotein, CoronavirusGamma-like-II and new mutationsPhylogenetic analyses of SARS-CoV-2VOC Gamma

Identifiers

PMID34789293
PMCPMC8596384
OpenAlexW3213840138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.